- Home
- DAVA vs FHTX Comparison
DAVA vs FHTX Comparison
Compare DAVA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | FHTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 173.4M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAVA | FHTX |
|---|---|---|
| Price | $1.89 | $1.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $5.30 | ★ $9.89 |
| AVG Volume (30 Days) | 839.1K | ★ 997.2K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.35 | $15.98 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.60 | $1.79 |
| 52 Week High | $9.88 | $7.61 |
Technical Indicators
Market Signals| Indicator | DAVA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 12.48 |
| Support Level | N/A | N/A |
| Resistance Level | $3.14 | $5.35 |
| Average True Range (ATR) | 0.16 | 0.28 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 21.94 | 7.99 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.